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A novel coronavirus has been identified as the etiologic agent of the recent worldwide outbreak of severe acute 
respiratory syndrome (SARS). Drug development for the treatment of SARS is urgently needed. Small interfering 
RNA (siRNA) is a double-stranded RNA (dsRNA) that directs the sequence-specific degradation of messenger 
RNA in mammalian cells. This offers the possibility of developing a new anti-viral therapy for SARS. Based on the 
complete coronavirus genomic sequence and the functional domains, we have designed six siRNAs targeting the 
replicase region of the virus. Here we describe the inhibition of coronavirus infection and replication by the 
synthetic 21- and 22-mer siRNAs. 
We designed six 21-mer siRNAs targeting different sites of the SARS-CoV replicase 1A. The anti-SARS-CoV 
activities of these siRNAs were tested in monkey kidney cells (FRhk-4 cells). FRhk-4 cells were transfected with 
siRNAs, and then infected with one isolate of SARS-CoV. As compared to the uninfected cells, cells infected with 
SARS-CoV exhibited a marked morphological change with CPE. Sarsi-2, sarsi-3 and sarsi-4 markedly inhibited the 
CPE caused by viral infection and replication , whereas sarsi-1, sarsi-5 and sarsi-6 were less effective judged by 
morphological changes. The results were further confirmed by immunostaining with antibody against SARS-CoV 
antigens. Consistently, the viral titers as determined by quantitative RT-PCR were reduced 92.5%, 89.6% and 
85.8% by sarsi-4, sarsi-2, and sarsi-3, respectively, but only 50% to 65% by the other three siRNAs. Furthermore, 
the effective sarsi-2,3,4 also inhibited the infection and replication of other different strains of SARS-CoV isolates. 
